Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer faces growth challenges with patent losses and waning COVID sales. Selling an ATM Put option expiring Nov'25 could ...

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Pfizer sold the five-building facility on Science Center Drive in Torrey Pines to BioMed Realty, a San Diego-based firm owned ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...